Biopharma BD&L Summit

New industry regulations bring with them increased costs, which lowers the R&D productivity of the entire industry. It is faster and more efficient to acquire an innovative therapeutic than to develop it in-house, but that requires a sharp focus on searching out and evaluating new candidates for mergers and acquisitions – and then negotiating the best deal that’s a win-win for everyone! DGE’s Biopharma BD&L Summit provides an unequaled in-depth examination of partnership strategies, licensing priorities, and ways to avoid everything that can go wrong with your next big merger. With the pandemic slowing down R&D, innovative deal structures can help your team still come out on top – so don’t miss out on this unique learning and networking opportunity, presented via a proven interactive online platform.